Show simple item record

The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ

dc.contributor.authorZuzarte, Louise
dc.contributor.authorMirhadi, Sara
dc.contributor.authorCarr, Richard
dc.contributor.authorTso, Simon
dc.date.accessioned2023-12-08T16:34:47Z
dc.date.available2023-12-08T16:34:47Z
dc.date.issued2019-11
dc.identifier.citationZuzarte L, Mirhadi S, Carr RA, Tso S. The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ. BMJ Case Rep. 2019 Nov 14;12(11):e232536. doi: 10.1136/bcr-2019-232536.en_US
dc.identifier.eissn1757-790X
dc.identifier.doi10.1136/bcr-2019-232536
dc.identifier.pmid31732538
dc.identifier.urihttp://hdl.handle.net/20.500.14200/3158
dc.description.abstractA case report of an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ.en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc6887357/en_US
dc.subjectDermatologyen_US
dc.subjectOncology. Pathology.en_US
dc.titleThe dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situen_US
dc.typeArticle
dc.source.journaltitleBMJ Case Reports
rioxxterms.versionNAen_US
dc.contributor.trustauthorZuzarte, Louise
dc.contributor.trustauthorMirhadi, Sara
dc.contributor.trustauthorCarr, Richard A.
dc.contributor.trustauthorTso, Simon
dc.contributor.departmentDermatologyen_US
dc.contributor.departmentHistopathologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.affiliationSouth Warwickshire University NHS Foundation Trusten_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record